Literature DB >> 1783444

The in vitro activity of flomoxef compared to four other cephalosporins and imipenem.

P M Shah1, H Knothe.   

Abstract

The antibacterial activity of the oxacephalosporin flomoxef was evaluated in comparison to cefpirome, cefuzoname, cefotaxime, ceftazidime, and imipenem against fresh clinical isolates. Flomoxef is an antibiotic with strong antibacterial activity against staphylococci including methicillin-resistant strains and streptococci with the exception of Enterococcus faecalis and Enterococcus faecium. It is very active against gram-negative cocci and rods including gram-positive and gram-negative anaerobes. Against Pseudomonas sp. flomoxef has no activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783444     DOI: 10.1007/bf01645540

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  2 in total

1.  Production of low-affinity penicillin-binding protein by low- and high-resistance groups of methicillin-resistant Staphylococcus aureus.

Authors:  K Murakami; K Nomura; M Doi; T Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins.

Authors:  K Yazawa; Y Mikami; J Uno; K Otozai; T Arai
Journal:  J Antimicrob Chemother       Date:  1989-12       Impact factor: 5.790

  2 in total
  3 in total

Review 1.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 2.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 3.  Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Christopher A Darlow; Renata M A da Costa; Sally Ellis; François Franceschi; Mike Sharland; Laura Piddock; Shampa Das; William Hope
Journal:  Paediatr Drugs       Date:  2021-08-26       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.